Found 941 clinical trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma (TIDE-asthma)
This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma. Study details include: The study duration (per participant) will be …
- 6 views
- 17 Nov, 2022
- 5 locations
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)
Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former …
- 722 views
- 16 Nov, 2022
- 68 locations
Dupilumab in CRSsNP (Liberty CRSsNP ORION)
Primary Objective: Part A and B: To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan and sinus total symptom score (sTSS) compared to placebo Secondary Objectives: Part A To evaluate the efficacy of dupilumab as assessed by …
- 20 views
- 09 Nov, 2022
- 9 locations
Nasal Polyps w/CRS
The aim of the present study is to investigate the efficacy and safety of Tezepelumab in participants with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
- 0 views
- 29 Sep, 2022
- 1 location
Albuterol in Patients With Lymphangioleiomyomatosis
Background: Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow of air. It is a progressive disease, and in severe cases may require a lung transplant. One possible treatment to …
- 94 views
- 22 Dec, 2020
- 1 location
A Phase III Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease.
This study will enroll approximately 800 patients with moderate to severe COPD in 2 subsets. The 24-week subset will enroll approximately 400 patients randomized 1:1 ensifentrine (3 mg): placebo and the 48-week subset will enroll approximately 400 patients randomized 3:1 in order to minimize the number of patients assigned to …
- 183 views
- 23 Nov, 2020
- 1 location
COPD Research Study for those with currently using inhaled medications (triple therapy) and have required an oral steroid for a flare in breathing 1-2 times in the last 12 months.
This investigational study is enrolling moderate to severe COPD subjects. To qualify you must be on inhaled maintenance medications and have required oral steroids 1-2 times or a hospitalization in the last year. Pulmonary function test will be performed and compensation will be provided for those who qualify.
- 147 views
- 23 Nov, 2020
- 1 location
COPD Exacerbation Research Study
Looking for patients at least 40 years of age who have been diagnosed with COPD and recently had several events of worsening of symptoms.
- 133 views
- 23 Nov, 2020
- 1 location
NO 0050-0637
ICON Early Phase Services is conducting a non-interventional device research study adults age 40+ who are either healthy, or, have chronic obstructive pulmonary disease (COPD). This study is being done to test the potential of using devices to help manage disease symptoms. Participants will complete a screening visit to determine …
- 613 views
- 23 Nov, 2020
- 1 location
Add on treatment for COPD for patients who experience frequent exacerbations
Current or former smokers who are diagnosed with COPD and experienced at least 2 exacerbations- worsening of symptoms requiring steroid treatment or hospitalization despite being on multiple inhaler medications may qualify for this study involving benralizumab subcutaneous injections compared to placebo injections, initially every 4 weeks, then every 8 weeks …
- 0 views
- 09 Jun, 2022
- 1 location